The purpose of this investigation was to determine the effects of thromboxane synthase inhibition on vascular responsiveness. To 
Introduction
Norepinephrine (NE)' and angiotensin II (All) are well-known examples of vasoconstrictors that mobilize arachidonate from phospholipid stores (1) (2) (3) (4) (5) (6) (7) and, thereby, accelerate the rate of prostaglandin (PG) endoperoxide biosynthesis. PG endoperoxides are further processed via alternative metabolic pathways to either thromboxane A2 (TXA2), PGI2, PGE2, PGD2, or PGF2< .
1. Abbreviations used in this paper: All, angiotensin II; NE, norepinephrine; PG, prostaglandin; PNS, periarterial nerve stimulation; TXA2, thromboxane.
Therefore, the profile of vasoconstrictor-induced prostanoid biosynthesis will depend upon the relative proximities and activities of the various enzymes catalyzing the transformation of PG endoperoxides.
One approach of altering the profile of vasoconstrictor-induced prostanoid biosynthesis would be to administer a TXA2 synthase inhibitor. By inactivating TXA2 synthase, PG endoperoxides that would have been transformed into TXA2 would now be available for PG12, PGD2, PGE2, or PGF2a biosynthesis. Evidence for "endoperoxide shunting" by TXA2 synthase inhibitors is abundant (8) (9) (10) (11) (12) .
If TXA2 synthase inhibitors alter the profile of vasoconstrictor-induced prostanoid biosynthesis, this could modify the vascular response to vasoconstrictors and sympathetic nerve stimulation. PGI2, PGD2, and PGE2 attenuate the vascular response to vasoconstrictors and inhibit the release of NE from noradrenergic varicosities (13) (14) (15) (16) (17) (18) . In contrast, TXA2 may potentiate the vascular response to vasoconstrictors (19, 20) . Therefore, a drug-induced shift from TXA2 synthesis and towards the synthesis of other prostanoids may attenuate the vascular response to vasoconstrictors and sympathetic nerve stimulation. The purpose of the present work is to test the hypothesis that inhibition ofTXA2 synthase results in an attenuation ofthe vascular response to sympathetic nerve stimulation, NE, or AII.
Methods
As summarized in Table I, 11 separate protocols involving 142 animals were conducted over the course of 2 yr. In each protocol an equal number of rats (either six or seven) were randomly assigned to receive either a particular TXA2 synthase inhibitor or the vehicle ofthat inhibitor (either olive oil or water). Thus, in each protocol a parallel group of control animals was randomized with the treatment group so that in no case was a historical control used for comparison. The protocols differed in five ways, i.e., type of TXA2 synthase inhibitor (either UK38,485, OKY1581, or U-63557A), dose of TXA2 synthase inhibitor (either 30 or 100 mg/kg), duration of treatment with a TXA2 synthase inhibitor (either single dose or daily doses over 7 d), presence or absence of cyclooxygenase inhibition, and rat strain (either Sprague-Dawley or spontaneously hypertensive rats). UK38,485 was suspended in olive oil, whereas OKY 1581 and U-63557A were dissolved in water. All TXA2 synthase inhibitors and vehicles of TXA2 synthase inhibitors were administered by gavage between 8:00 and 9:00 a.m. Cyclooxygenase inhibition was achieved by administering subcutaneously 5 mg/kg of indomethacin suspended in olive oil 24, 12, and 2 h before assessment of vascular responsiveness. This dose ofindomethacin was previously shown to block cyclooxygenase activity in the rat mesentery (21) . In all protocols, vascular responsiveness was assessed -2 h after the last dose of the TXA2 synthase inhibitor or its vehicle.
Mesenteric vascular responsiveness was assessed using the in situ perfused mesentery technique previously described by Jackson and Campbell (22) . Briefly, each animal was anesthetized with pentobarbital (50 mg/kg, i.p.), and a cannula was inserted into the abdominal aorta below the renal and mesenteric arteries. An extracorporeal shunt was established between the abdominal aorta and the superior mesenteric artery using a Harvard peristaltic pump (Harvard Apparatus Co., Inc., (24) . TXB2 levels in serum from clotted blood reflect platelet TXA2 synthase activity (25) (26) (27) at the ambient plasma levels of the inhibitor.
Further experiments were performed to determine whether or not the degree of platelet TXA2 synthase inhibition was the same 2 h after a single dose of UK38,485 vs. 2 h after the last dose of a week-long pretreatment with UK38,485. In these experiments Sprque-Dawley rats were given either 100 mg/kg of UK38,485 or olive oil (1 ml/kg) by gavage. Some animals had been pretreated for 7 d with daily doses of UK38,485 (100 mg/kg) or olive oil, whereas others had not been pretreated. 2 h later, the rats were decapitated and blood samples collected. TXB2 levels were determined in sera from these samples as described above. Figure 7 . Effects of a single oral dose of UK38,485 (100 mg/kg) on vascular responsiveness to AII in Sprague-Dawley rats pretreated with indomethacin (5 mg/kg X three doses, subcutaneously). Fig. 17, left panel) and All (Fig. 18 ), but did not alter the vascular response to exogenous NE (Fig. 17, right panel) . Protocols 9, 10, and 11. The effects ofa third TXA2 synthase inhibitor, U-63557A, on vascular responsiveness in the hypertensive rat also were examined. Chronic administration of U-63557A (100 mg/kg. d X 7 d) markedly suppressed the vascular response to PNS (Fig. 19, left panel) , exogenous NE (Fig. 19 , right panel), and All (Fig. 20) . However, vascular responses to PNS were suppressed to a greater extent by U-63557A than were responses to NE. Also U-63557A suppressed the vascular response to PNS more than did either UK38,485 or OKY1581. For replication, the reduction in the mean response to PNS by U-63557A was significantly (P < 0.05) greater than the reduction achieved with either UK38,485 or OKY 1581.
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The effect of chronic U-63557A administration (100 mg/ kg d X 7 d) on vascular responsiveness in indomethacin-pretreated hypertensive rats also was investigated. In indomethacinpretreated animals U-63557A did not significantly suppress vascular responses to either PNS (Fig. 21, left panel) , exogenous NE (Fig. 21, right panel) , or All (Fig. 22) . When all hypertensive control rats receiving indomethacin were compared to all hypertensive control rats not receiving indomethacin, indomethacin was found not to depress the vascular response to PNS, exogenous NE, or All (data from Figs. 12-23 ). Like UK38,485, lower chronic doses of U-63557A (30 mg/kg. d X 7 d) did not influence vascular responsiveness (Fig. 23) . This occurred despite the fact that 30 and 100 mg/kg doses of U-63557A produced equivalent inhibition of platelet TXA2 synthase activity during the first 3 h after administration (Fig. 2) .
Base The vascular response to All was reduced by chronic administration of UK38,485, OKY 1581, and U-63557A. All three inhibitors attenuated the vascular response to All by a similar amount, indicating that the observed effect was due specifically to inhibition ofTXA2 synthase and not a result ofsome'unknown nonspecific action of any one inhibitor. Unlike TXA2 synthase inhibition, cyclooxygenase inhibition did not attenuate the vascular response to All. However, in animals pretreated with indomethacin, TXA2 synthase inhibition failed to attenuate All responses. This was confirmed in three separate experiments. These observations suggest that the attenuation of vascular responses to All by TXA2 synthase inhibition is due primarily to either enhanced prostaglandin biosynthesis per se, presumably due to endoperoxide shunting, or to enhanced prostaglandin production in combination with a reduction in TXA2 levels.
A critical issue raised by these observations relates to the site ofthe putative endoperoxide shunting responsible for attenuating vascular responses to All. Platelets are a rich source of TXA2 synthase (29) , and platelet-endothelial interactions would pro- vide the prerequisite arrangement of enzymes necessary for enabling endoperoxide shunting. However, if platelet-endothelial interactions were responsible for the endoperoxide shunting that attenuates responses to All, then both acute and chronic administration of UK38,485 should reduce the vascular response to All. In contrast to this prediction, even though acute and chronic administration of UK38,485 caused equivalent inhibition ofplatelet TXA2 synthase at the time vascular responsiveness was assessed, only chronic treatment attenuated the vascular response to All. This result excludes platelet-endothelial interactions as the source of endoperoxide shunting responsible for attenuating vascular responses to All. Instead, the novel concept that endoperoxide shunting may occur within the blood vessel is supported. Because time would be required for penetration of UK38,485 into the blood vessel wall, this hypothesis would explain the observation that chronic, but not acute, administration of UK38,485 attenuates the vascular response to All.
The effects of chronic administration of UK38,485 on vascular responses to All in both normotensive and hypertensive rats were investigated. TXA2 production may be elevated in the spontaneously hypertensive rat (30, 31) and, therefore, the effects of TXA2 synthase inhibitors may be more pronounced in this strain. However, UK38,485 attenuated vascular responses similarly in both normotensive and hypertensive rats and, in both cases, the attenuation was blocked with indomethacin. Therefore, a greater role for TXA2 synthase activity in spontaneously hypertensive rats is not supported. Chronic administration of UK38,485, OKY 1581, and U-63557A also attenuated the vascular response to sympathetic nerve stimulation. Like the response to AII, the response to sympathetic nerve stimulation was not attenuated significantly by acute treatment with UK38,485. Further, chronic treatment with lower doses of UK38,485 and U-63557A did not alter vascular responsiveness to sympathetic nerve stimulation, despite the fact that platelet TXA2 synthase activity was nearly abolished at the time vascular reactivity was assessed. Again, these data indicate that the relevant pool of TXA2 synthase does not lie within the platelet, rather the attenuation of vascular responsiveness to nerve stimulation by TXA2 synthase inhibition is due to inhibition of some less accessible pool of TXA2 synthase such as the blood vessel wall, or perhaps even the sympathetic neuroeffector junction.
The mechanism of attenuation of responses to sympathetic nerve stimulation by TXA2 synthase inhibition also appears to be due to endoperoxide shunting. Cyclooxygenase inhibition did not reduce the response to sympathetic nerve stimulation, yet in three separate studies cyclooxygenase inhibition prevented the attenuating effects of TXA2 synthase inhibition on vascular responsiveness to sympathetic nerve stimulation. These observations are inconsistent with an exclusive role for TXA2, but are consistent with the hypothesis that endoperoxide shunting enhances prostaglandin biosynthesis and prostaglandins, either per se or in combination with the reduction in TXA2 levels, then attenuate the response to nerve stimulation.
Like attenuation of All responses, the attenuation of responses to sympathetic nerve stimulation by TXA2 synthase inhibition was similar in normotensive and hypertensive rats. Again, these data do not support a greater role for TXA2 synthase in spontaneously hypertensive rats.
The results obtained in these studies clearly indicate that chronic inhibition of TXA2 synthase attenuates the overall neurotransmission process, most likely via a prostaglandin-dependent mechanism. Prostaglandins can attenuate sympathetic neurotransmission by two basic mechanisms, i.e., by decreasing neurotransmitter release or by reducing the postjunctional responsiveness to NE (13) (14) (15) (16) (17) (18) . The first mechanism would alter the effector organ response to nerve activation, but would not modify the effector response to exogenously administered neu- rotransmitter. In contrast, a postjunctional change in the relationship between neurotransmitter concentration and end-organ response usually would alter the response to both nerve activation and exogenously applied neurotransmitter. Implicit in this latter statement is the assumption that receptor-effector coupling at sites activated by endogenous neurotransmitter is influenced similarly to coupling at receptor sites activated by exogenous neurotransmitter. Because chronic administration ofUK38,485 and OKY 1581 reduced the vascular response to PNS, without altering the vascular response to exogenous norepinephrine, it appears that these two agents attenuate nerve stimulation-induced exocytosis, but do not alter postjunctional responsiveness to NE. On the other hand, chronic administration of U-63557A attenuated the vascular response to both PNS and exogenous NE; however, the magnitude of the displacement of the frequency-response curve was greater than the displacement of the norepinephrine dose-response curve. Further, the attenuation of the vascular response to PNS by U-63557A was greater than that obtained with either UK38,485 or OKY1581. These data are consistent with the hypothesis that U-63557A acts similarly *-* Vehicle Group In a previous short communication, I reported that chronic administration of UK38,485 attenuates the vascular response to sympathetic nerve stimulation, but not to exogenous NE, in the normotensive rat (32) . This observation was confirmed and extended in the present study. In the previous study, the effect of chronic UK38,485 administration on the vascular response to All also was examined and found not to be statistically significant. However, only the peak responses to All were compared, rather than the response over a 10-min infusion. When the latter approach is used the vascular response to All is statistically significantly attenuated by chronic administration of UK38,485.
In conclusion, chronic administration of TXA2 synthase inhibitors attenuates vascular responses to All and sympathetic nerve stimulation, but not usually to NE. These effects are blocked, but not mimicked, by cyclooxygenase inhibition. Further, the altered vascular responsiveness induced by TXA2 synthase inhibitors does not correlate with platelet TXA2 synthase activity. Taken together, my observations suggest that chronic TXA2 synthase inhibition reduces vascular responsiveness perhaps by causing endoperoxide shunting within the blood vessel wall.
